Publications | R2M Pharma

top of page

Novel series of tunable µOR modulators with enhanced brain penetration for the treatment of opioid use disorder, pain and neuropsychiatric indications

Bioorganic & Medicinal Chemistry Letters

Volume 92

August 15, 2023

EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive–compulsive disorder (OCD)-like behaviors

Frontiers in Psychiatry

Volume 14 - 2023

June 30, 2023

Phenotypic Screening with Deep Learning Identifies HDAC6 Inhibitors As Cardioprotective in a BAG3 Mouse Model of Dilated Cardiomyopathy

Science Translational Medicine

Volume 14, Issue 652

July 6, 2022

A Novel Maintenance Therapeutic for Opioid Use Disorder

The Journal of Pharmacology and Experimental Therapeutics

Volume 368, Issue 2

August 1, 2021

Phenotypic Screening Identifies HDAC6 Inhibitors as Cardioprotective Agents

2021 European Society of Cardiology - Heart Failure Congress

July 29, 2021

Optimization of Novel μOR Ligands for Enhanced CNS Penetration

Presented at the ACS Fall 2020 Virtual Meeting & Expo

August 17-20, 2020

Control of the μ-Opioid Receptor Efficacy In Vitro and In Vivo by Novel Conformationally Restricted Cyclopropane Carboxamide-derived Cis/Trans Isomers

Presented at the ACS Fall 2020 Virtual Meeting & Expo

August 17-20, 2020

Novel Partial Mu Opioid Agonists for the Treatment of Opioid Use Disorder

Presented at the NIH HEAL Investigators Meeting

January 16-17, 2020

bottom of page